Sign in
Enrolling by invitationPhase 3

Long-term follow-up of people with sickle cell disease treated with gene therapy

Follows people with sickle cell disease who received gene therapy, for 15 years.

Key facts

Who runs it
Genetix Biotherapeutics Inc.
Where
Atlanta, Bethesda, Birmingham, Chapel Hill, Charleston, Chicago, Durham, Hackensack, Houston, Minneapolis, New Hyde Park, New York, Oakland, Philadelphia, and Richmond, United StatesSee the 15 sitesAlso in 1 other country, 1 site
Registry title
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
Status
Enrolling by invitation
Phase
Phase 3
People taking part
85 people, planned
Started
21 Oct 2020
Expected to end
Jan 2038
Type of study
Observational
Treatments tested
  • Safety and efficacy assessments
Record updated
20 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with sickle cell disease who already received gene therapy in a bluebird bio-sponsored study. They are followed for a total of 15 years after the infusion.

Age
2 Years to 53 Years
Sex
All sexes can join.
Earlier treatment
Must have been treated with the gene therapy drug product for sickle cell disease in a bluebird bio-sponsored clinical study.

Main reasons for not taking part

  • The record lists no exclusion criteria.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/legal guardian(s)
  • Treated with drug product for therapy of sickle cell disease in a bluebird bio-sponsored clinical study

Who cannot take part

  • There are no exclusion criteria for this study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 53 years old?

Where in United States

Also in 1 other country, 1 site

  • Children's Healthcare of AtlantaAtlanta, United StatesEnrolling by invitation
  • Warren Grant Magnuson Clinical CenterBethesda, United StatesEnrolling by invitation
  • University of AlabamaBirmingham, United StatesEnrolling by invitation
  • The University of North CarolinaChapel Hill, United StatesEnrolling by invitation
  • Medical University of South CarolinaCharleston, United StatesEnrolling by invitation
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesEnrolling by invitation
  • Duke University Medical CenterDurham, United StatesEnrolling by invitation
  • Hackensack University Medical CenterHackensack, United StatesEnrolling by invitation
  • Baylor College of MedicineHouston, United StatesEnrolling by invitation
  • University of Minnesota/Masonic Children's HospitalMinneapolis, United StatesEnrolling by invitation
  • Cohen Children's Medical CenterNew Hyde Park, United StatesEnrolling by invitation
  • Columbia University Medical CenterNew York, United StatesEnrolling by invitation
  • UCSF Benioff Children's Hospital OaklandOakland, United StatesEnrolling by invitation
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
  • Virginia Commonwealth UniversityRichmond, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This is a multi-center, long-term safety and efficacy follow-up study for subjects with sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After completing the parent clinical study (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in the study.

The group in the trial

  • Subjects with sickle-cell disease

    Subjects treated with ex vivo gene therapy drug product for sickle cell disease in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study

    Treatment: Safety and efficacy assessments

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector
Plain-language title
Long-term follow-up of people with sickle cell disease treated with gene therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04628585, who can take part
Publications
Record updated
20 March 2025